Supplementary Data — Resveratrol for COVID-19: real-time meta analysis of 3 studies

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCreary (DB RCT) 67% 0.33 [0.04-3.10] hosp. 1/50 3/50 Improvement, RR [CI] Treatment Control McCreary (DB RCT) 43% 0.57 [0.18-1.83] progression 4/50 7/50 McCreary (DB RCT) 50% 0.50 [0.16-1.55] progression 4/50 8/50 McCreary (DB RCT) 0% 1.00 [0.06-15.5] progression 1/50 1/50 RESCU 002 Mittra 44% 0.56 [0.26-1.02] death 7/30 89/200 CT​1​ Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] ventilation 1/14 1/16 CT​1​ Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] ICU 1/14 1/16 CT​1​ Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] hosp. 1/14 1/16 CT​1​ Resveratrol COVID-19 outcomes c19early.org November 2025 ​1​ CT: study uses combined treatment Favors resveratrol Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.